Medical student exposure to and attitudes about pharmaceutical companies

Wisconsin Medical Journal

Volumn 109, Issue 3, 2010, Pages 142-148

  Soyk, Cody ^a   Pfefferkorn, Branden ^b   McBride, Patrick ^a   Rieselbach, Richard ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Swedish/Cherry Hill Family Medicine Residency   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONFLICT OF INTEREST; DRUG INDUSTRY; DRUG MARKETING; HEALTH SURVEY; HUMAN; HUMAN RELATION; MEDICAL STUDENT; PUBLIC HEALTH; QUESTIONNAIRE; SOCIAL INTERACTION; STUDENT ATTITUDE; UNITED STATES;

ATTITUDE OF HEALTH PERSONNEL; CHI-SQUARE DISTRIBUTION; DRUG INDUSTRY; FEMALE; GIFT GIVING; HUMANS; INTERPROFESSIONAL RELATIONS; MALE; QUESTIONNAIRES; STUDENTS, MEDICAL; WISCONSIN; YOUNG ADULT;

EID: 77956246896     PISSN: 10981861     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Gagnon MA, Lexchin J. The cost of pushing pills: a new estimateof pharmaceutical promotion expenditures in the United States. PLoS Med. 2008;5:e1.
2. Bodenheimer T. Uneasy alliance: clinical investigatorsand the pharmaceutical industry. N Engl J Med.2000;342:1539-1543.
3. Brodkey AC. The role of industry in teaching psychopharmacology:a growing problem. Acad Psychiatry.2005;29:222-229.
4. Wolfe SM. Why do American drug companies spend morethan $12 billion a year pushing drugs? J Gen Intern Med.1996;11:637-639.
5. Woosley RL. Centers for education and research in therapeutics.Clin Pharmacol Ther. 1994;55:249.
6. Drake D, Uhlman M. Making Medicine, Making Money.Kansas City, Mo: Andrews & McMeel; 1993.
7. Randall T. Kennedy hearings say no more free lunch or much else from drug firms. JAMA. 1991;265:440-442.
8. Moynihan R. Who pays for the pizza? redefining the relationshipsbetween doctors and drug companies. 1: entanglement.BMJ. 2003;326:1189-1192.
9. Wazana A. Physicians and the pharmaceutical industry: is agift ever just a gift? JAMA. 2000;283(3):373-380.
10. Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician-industry relationships.N Engl J Med. 2004;351(18):1885-1890.
11. Henry J. Kaiser Family Foundation. National survey of physicians,part II: doctors and prescription drugs. Washington,DC: Kaiser Family Foundation, 2002. http://www.kff.org/rxdrugs/upload/Highlights-and-Chartpack.pdf. Accessed April26, 2010.
12. Orlowski JP, Wateska L. The effects of pharmaceutical firmenticements on physicians' prescribing patterns: there's nosuch thing as a free lunch. Chest. 1992;102:270-273.
13. Prosser H, Almond S, Walley T. Influences on GPs' decisionsto prescribe new drugs: the importance of who says what.Fam Pract. 2003;20:61-68.
14. Haayer F. Rational prescribing and sources of information.Soc Sci Med. 1982;16:2017-2023.
15. Bower AD, Burkett GL. Family physicians and generic drugs J Fam Pract. 1987;24:612-616.
16. Lurie N, Rich EC, Simpson DE, et al. Pharmaceutical representativesin academic medical centers. J Gen Intern Med.1990;5:240-243.
17. Caudill T, Johnson M, Rich E, McKinney P. Physicians, pharmaceuticalsales representatives, and the cost of prescribing.Arch Fam Med. 1996;5:201-206.
18. Bower A, Burkett G. Family physicians and generic drugs:a study of recognition, information sources, prescribing attitudes,and practices. J Fam Pract. 1987;24:612-616.
19. Sierles FS, Brodkey AC, Cleary LM, et al. Medical students' exposure to and attitudes about drug company interactions: anational survey. JAMA. 2005;294:1034-1042.
20. Steinman MA, Shlipak MG, McPhee SJ. Of principlesand pens: attitudes and practices of medicine housestafftoward pharmaceutical industry promotions. Am J Med.2001;110:551-557.
21. McKinney W, Schiedermayer D, Lurie N, Simpson D, Goodman J, Rich E. Attitudes of internal medicine faculty andresidents toward professional interaction with pharmaceuticalsales representatives. JAMA. 1990;264:1693-1697.
22. Palmisano P, Edelstein J. Teaching drug promotion abuses tohealth profession students. J Med Educ. 1980;55:453-455.
23. Caudill TS, Johnson MS, Rich EC, McKinney WP. Physicians, pharmaceutical sales representatives and thecost of prescribing. Arch Fam Med. 1996;5:201-206.
24. Hodges B. Interactions with the pharmaceutical industry. CMAJ. 1995;153:553-559.
25. Reeder M, Dougherty J, White LJ. Pharmaceutical representatives and emergency medicine residents. Ann Emerg Med.1993;22:105-108.
26. Banks JW, Mainous AG. Attitudes of medical school faculty toward gifts from the pharmaceutical industry. Acad Med.1992;67:610-612.
27. Wilkes MS, Hoffman JR. An innovative approach to educatingmedical students about pharmacological promotion. AcadMed. 2001;76:1271-1277.
28. Monaghan MS, Galt KA, Turner PD, et al. Student understanding of the relationship between the health professions and the pharmaceutical industry. Teach Learn Med.2003;15:14-20.
29. Sandberg WS, Carlos R, Sandberg EH, Roizen MF. The effect of educational gifts from pharmaceutical firms on medicalstudents' recall of company names or products. Acad Med.1997;72:916-918.
30. Dana J, Loewenstein G. A social science perspective on giftsto physicians from industry. JAMA. 2003;290(2):252-255.
31. Hyman PL, Hochman ME, Shaw JG, Steinman MA. Attitudes of preclinical and clinical medical students toward interactions with the pharmaceutical industry. Acad Med. 2007;82(1):94-99.
32. Monaghan MS, Galt KA, Turner PD, et al. Student understanding of the relationship between the health professions and the pharmaceutical industry. Teach Learn Med. 2003;15:14-20.
33. Bellin M, McCarthy S, Drevlow L, Pierach C. Medical students' exposure to pharmaceutical industry marketing: a survey at one US medical school. Acad Med. 2004;79:1041-1045.
34. Fitz MM, Homan D, Reddy S, Griffith CH III, Baker E, Simpson KP. The hidden curriculum: medical students' changing opinions toward the pharmaceutical industry. Acad Med. 2007;82(10 Suppl):S1-S3.
35. AMSA PharmFree Scorecard 2009. http://amsascorecard. org. Reston, VA: American Medical Student Association. Accessed April 26, 2010.
36. Wilson D. Harvard Medical School in Ethics Quandary. New York Times: March 2, 2009:B1.
37. Brody H. The company we keep: why physicians should refuse to see pharmaceutical representatives. Ann Fam Med. 2005;3(1):82-85.
38. Greenland P. Time for the medical profession to act: new policies needed now on interactions between pharmaceutical companies and physicians. Arch Intern Med. 2009;169(9):829-831.
39. Alkhateeb FM, Khanfar NM, Clauson KA. Characteristics of physicians who frequently see pharmaceutical sales representatives. J Hosp Mark Public Relations. 2009;19(1):2-14.
40. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995;273:1296-1298.